Rezolute, Inc.
RZLTNasdaq
$4.61
↑ +5.5%Jul 17 close · end-of-day
Price
1Y↓ -13.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$479.6M
Enterprise Value
$359.4M
P/E
—
P/S
—
P/B
4.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$81.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-69.7%
ROIC
—
Debt / Equity
—
Net Cash
$120.3M
Return 1Y
-16.8%
Company profile
Rezolute, Inc. develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
- CEO
- Nevan C. Elam
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- California
- Website
- rezolutebio.com
Management & directors
- Elam Nevan CCEO
- Evans DaronCFO
- Roberts Brian KennethChief Medical Officer
- Karnawat Sunil RatilalChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
RZLT Q3 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.16↓ -40.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$22.9M | -$41.8M | -$56.0M | -$70.4M | -$79.9M |
| Net income | -$20.9M | -$41.1M | -$51.8M | -$68.5M | -$74.4M |
| Diluted EPS | -$2.72 | -$2.32 | -$1.01 | -$1.33 | -$0.98 |
| Operating cash flow | -$20.4M | -$39.6M | -$44.5M | -$57.4M | -$69.1M |
| Free cash flow | — | — | -$44.6M | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$23.1M | -$16.9M | -$17.1M | -$20.0M | -$25.9M | -$19.8M | -$24.2M | -$17.4M |
| Net income | -$23.0M | -$15.4M | -$15.7M | -$18.9M | -$24.4M | -$18.1M | -$22.8M | -$16.2M |
| Diluted EPS | -$0.44 | -$0.22 | -$0.22 | -$0.27 | -$0.27 | -$0.18 | -$0.22 | -$0.16 |
| Operating cash flow | -$18.5M | -$16.0M | -$13.7M | -$17.4M | -$22.0M | -$17.4M | -$20.3M | -$13.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 4, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | Elam Nevan C· CEO | Tax withholding | 8,004 | $4.99 | $39,939.96 | filing |
| 2026-07-02 | Evans Daron· CFO | Tax withholding | 3,062 | $4.99 | $15,279.38 | filing |
| 2026-07-02 | ROBERTS BRIAN KENNETH· Chief Medical Officer | Tax withholding | 3,062 | $4.99 | $15,279.38 | filing |
| 2026-03-30 | Evans Daron· CFO | Buy | 10,000 | $2.85 | $28,500.00 | filing |
| 2026-03-02 | Elam Nevan C· CEO | Tax withholding | 27,618 | $2.99 | $82,577.82 | filing |
| 2026-03-02 | ROBERTS BRIAN KENNETH· Chief Medical Officer | Tax withholding | 11,439 | $2.99 | $34,202.61 | filing |
| 2026-03-02 | Evans Daron· CFO | Tax withholding | 11,438 | $2.99 | $34,199.62 | filing |
| 2025-12-16 | ROBERTS BRIAN KENNETH· Chief Medical Officer | Buy | 28,000 | $1.70 | $47,600.00 | filing |
| 2025-12-16 | Hogenhuis Wladimir | Buy | 5,650 | $1.69 | $9,548.50 | filing |
| 2025-12-15 | Evans Daron· CFO | Buy | 40,000 | $1.77 | $70,640.00 | filing |
| 2025-12-15 | Elam Nevan C· CEO | Buy | 32,000 | $1.59 | $50,880.00 | filing |
| 2025-12-15 | Karnawat Sunil Ratilal· Chief Commercial Officer | Buy | 12,000 | $1.62 | $19,438.80 | filing |
| 2025-12-15 | Evans Daron· CFO | Buy | 2,500 | $1.79 | $4,475.00 | filing |
| 2025-12-15 | Evans Daron· CFO | Buy | 2,500 | $1.79 | $4,462.50 | filing |
| 2025-12-15 | Karnawat Sunil Ratilal· Chief Commercial Officer | Buy | 100 | $1.60 | $160.00 | filing |
| 2025-11-19 | ROBERTS BRIAN KENNETH· Chief Medical Officer | Award | 123,000 | $0.00 | $0.00 | filing |
| 2025-11-19 | Karnawat Sunil Ratilal· Chief Commercial Officer | Award | 32,000 | $0.00 | $0.00 | filing |
| 2025-11-19 | Elam Nevan C· CEO | Award | 317,000 | $0.00 | $0.00 | filing |
| 2025-11-19 | Evans Daron· CFO | Award | 107,000 | $0.00 | $0.00 | filing |
| 2025-11-19 | KREHER NERISSA | Award | 21,000 | $0.00 | $0.00 | filing |
| 2025-11-19 | Hogenhuis Wladimir | Award | 21,000 | $0.00 | $0.00 | filing |
| 2025-11-19 | Harris Erik | Award | 21,000 | $0.00 | $0.00 | filing |
| 2025-11-19 | Kim Young-Jin | Award | 21,000 | $0.00 | $0.00 | filing |
| 2025-11-19 | FAUCHET PHILIPPE | Award | 21,000 | $0.00 | $0.00 | filing |
| 2025-11-19 | Labrucherie Gil M | Award | 21,000 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.